Evidence map›Paper›PMID 40482004›Full record

ReviewMolecular diagnosis & therapy2025

Current Methods in Clinical Alzheimer's Disease Research and Diagnosis.

Eleftheria Kodosaki, Henrik Zetterberg, Amanda Heslegrave

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diagnosis & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eleftheria KodosakiDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.ORCID 0000-0003-1086-6409
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.ORCID 0000-0003-3930-4354
Amanda HeslegraveDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. a.heslegrave@ucl.ac.uk.ORCID 0000-0002-7290-6405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early and accurate diagnosis of Alzheimer's disease is crucial for enabling timely intervention and improving patient outcomes. Recent advancements in molecular and imaging methodologies have significantly enhanced the detection of Alzheimer's disease at its early stages and have improved the quality of research in the field. Key molecular approaches include the identification of biomarkers such as amyloid-beta plaques and tau protein tangles, which are central to Alzheimer's disease pathology. These biomarkers can be detected through biofluid analysis or imaging methods, offering high sensitivity, however with disadvantages, which are discussed here. Despite the transition of some of these methods from research settings to clinical practice, several challenges persist, including the need for standardisation across diagnostic platforms and ensuring the accessibility of these advanced technologies within diverse healthcare systems. Additionally, the high cost and requirement for specialised expertise remain significant barriers. Here, we discuss the need to improve the effectiveness of early AD diagnosis, the ongoing research that is being conducted to refine biomarker detection, enhance imaging techniques and develop more cost-effective non-invasive diagnostic approaches. These advancements are essential to overcoming current limitations and ensuring a broader application in clinical settings.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersEarly DiagnosisHumanstau ProteinsAmyloid beta-PeptidesBiomarkerstau Proteins

Identifiers

PMID40482004

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.